0

Temsirolimus

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP162635043
CAS162635-04-3
Structure
MDL NumberMFCD00934421
Molecular Weight1030.29
InChI KeyCBPNZQVSJQDFBE-FUXHJELOSA-N
Description≥98% (HPLC)
SolubilityDMSO: ≥20 mg/mL
Assay≥98% (HPLC)
Colorwhite to off-white
Formpowder
Size5MG, 25MG
Storage Conditionsroom temp
1

A Phase II Study of Frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent Endometrial Cancer

Carol Aghajanian, Virginia Filiaci, Don S Dizon, Jay W Carlson, Matthew A Powell, Angeles Alvarez Secord, Krishnansu S Tewari, David P Bender, David M O'Malley, Ashley Stuckey, JianJiong Gao, Fanny Dao, etc.

Gynecol Oncol. 2018 Aug;150(2):274-281.

PMID: 29804638

1

Ibrutinib Versus Temsirolimus in Patients With Relapsed or Refractory Mantle-Cell Lymphoma: An International, Randomised, Open-Label, Phase 3 Study

Martin Dreyling, Wojciech Jurczak, Mats Jerkeman, Rodrigo Santucci Silva, Chiara Rusconi, Marek Trneny, Fritz Offner, Dolores Caballero, Cristina Joao, Mathias Witzens-Harig, Georg Hess, Isabelle Bence-Bruckler, etc.

Lancet. 2016 Feb 20;387(10020):770-8.

PMID: 26673811

1

Ibrutinib Versus Temsirolimus: 3-year Follow-Up of Patients With Previously Treated Mantle Cell Lymphoma From the Phase 3, International, Randomized, Open-Label RAY Study

S Rule, W Jurczak, M Jerkeman, C Rusconi, M Trneny, F Offner, D Caballero, C Joao, M Witzens-Harig, G Hess, I Bence-Bruckler, S-G Cho, C Thieblemont, W Zhou, T Henninger, J Goldberg, J Vermeulen, M Dreyling

Leukemia. 2018 Aug;32(8):1799-1803.

PMID: 29572505

1

Irinotecan-temozolomide With Temsirolimus or Dinutuximab in Children With Refractory or Relapsed Neuroblastoma (COG ANBL1221): An Open-Label, Randomised, Phase 2 Trial

Rajen Mody, Arlene Naranjo, Collin Van Ryn, Alice L Yu, Wendy B London, Barry L Shulkin, Marguerite T Parisi, Sabah-E-Noor Servaes, Mitchell B Diccianni, Paul M Sondel, Julia G Bender, John M Maris, Julie R Park, etc.

Lancet Oncol. 2017 Jul;18(7):946-957.

PMID: 28549783

1

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Gary Hudes, Michael Carducci, Piotr Tomczak, Janice Dutcher, Robert Figlin, Anil Kapoor, Elzbieta Staroslawska, Jeffrey Sosman, David McDermott, István Bodrogi, Zoran Kovacevic, Vladimir Lesovoy, Ingo G H Schmidt-Wolf, etc.

N Engl J Med. 2007 May 31;356(22):2271-81.

PMID: 17538086

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode